A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) | MicrobiomeTrials
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2022-06-17Est. Completion: 2026-10-30
Enrollment target: 200 participants
Locations
University of California San Francisco - Fresno Center for Medical Education and Research, Clovis, California, United States
Scripps Health - Prebys Cancer Center, San Diego, California, United States
Sylvester Comprehensive Cancer Center, Miami, Florida, United States
Miami Cancer Institute, Miami, Florida, United States
Memorial Cancer Institute - Memorial Hospital West, Pembroke Pines, Florida, United States
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
The Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States
Mission Cancer + Blood - Mission Cancer Foundation, Des Moines, Iowa, United States
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
University of Minnesota, Minneapolis, Minnesota, United States
Columbia University Irving Medical Center, New York, New York, United States
Cleveland Clinic Main Campus, Cleveland, Ohio, United States
Oregon Health and Science University, Portland, Oregon, United States
Other microbiome trials you might be interested in